Citations

Citations to this article as recorded by  

• Estimating Type 2 Diabetes Prevalence: A Model of Drug Consumption Data
  Rita Oliveira, Matilde Monteiro-Soares, José Pedro Guerreiro, Rúben Pereira, António Teixeira-Rodrigues
  Pharmacy.2024; 12(1): 18.     CrossRef
• Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
  Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
  Diabetes & Metabolism.2023; 49(4): 101440.     CrossRef
• Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double‐blind, and placebo‐controlled study
  Minyoung Lee, Woo‐je Lee, Jae Hyeon Kim, Byung‐Wan Lee
  Diabetes, Obesity and Metabolism.2022; 24(6): 1105.     CrossRef
• A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
  Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
  Diabetes, Obesity and Metabolism.2022; 24(9): 1800.     CrossRef
• Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial
  Jaehyun Bae, Ji Hye Huh, Minyoung Lee, Yong‐Ho Lee, Byung‐Wan Lee
  Diabetes, Obesity and Metabolism.2021; 23(2): 609.     CrossRef

Citations

Citations to this article as recorded by  

• What is the impact of ferroptosis on diabetic cardiomyopathy: a systematic review
  Xiaokun Lou, Yuanyuan Zhang, Junfeng Guo, Lina Gao, Yingying Ding, Xinyu Zhuo, Qingqing Lei, Jing Bian, Rumei Lei, Wenyan Gong, Xingwei Zhang, Qibin Jiao
  Heart Failure Reviews.2023; 29(1): 1.     CrossRef
• MiR-29a regulates cardiomyocyte apoptosis by targeting Bak1 in diabetic cardiomyopathy
  Xiaoyan Wang, Zhitao Zhang, Mei Wang
  The Journal of Biochemistry.2022; 171(6): 663.     CrossRef

Citations

Citations to this article as recorded by  

• Angiopoietin-like proteins in atherosclerosis
  Yi-Zhang Liu, Chi Zhang, Jie-Feng Jiang, Zhe-Bin Cheng, Zheng-Yang Zhou, Mu-Yao Tang, Jia-Xiang Sun, Liang Huang
  Clinica Chimica Acta.2021; 521: 19.     CrossRef

Citations

Citations to this article as recorded by  

• PCSK9 gene participates in the development of primary dyslipidemias
  D Matías-Pérez, AD Pérez-Santiago, MA Sánchez Medina, JJ Alpuche Osorno, IA García-Montalvo
  Balkan Journal of Medical Genetics.2021; 24(1): 5.     CrossRef

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

Citations

Citations to this article as recorded by  

• Anti-inflammatory effect of glucagon-like Peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model
  Yeon Woong Chung, Ji Young Lee, Hyun Hee Ju, Jin A. Choi
  European Journal of Pharmacology.2022; 933: 175269.     CrossRef
• Diabetes Risk Data Mining Method Based on Electronic Medical Record Analysis
  Yang Liu, Zhaoxiang Yu, Yunlong Yang, Zhihan Lv
  Journal of Healthcare Engineering.2021; 2021: 1.     CrossRef
• Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
  Doo Soo Jeon
  Cardiovascular Prevention and Pharmacotherapy.2020; 2(1): 11.     CrossRef
• The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
  Ju-Ming Lu
  Advances in Therapy.2019; 36(4): 798.     CrossRef
• A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
  Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego
  Diabetes Therapy.2019; 10(1): 5.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
  Hyun Jin Kim
  The Journal of Korean Diabetes.2018; 19(1): 35.     CrossRef

The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.

Citations

Citations to this article as recorded by  

• Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
  Eun-Gyoung Hong, Kyung-Wan Min, Jung Soo Lim, Kyu-Jeung Ahn, Chul Woo Ahn, Jae-Myung Yu, Hye Soon Kim, Hyun Jin Kim, Won Kim, Dong Han Kim, Hak Chul Jang
  Advances in Therapy.2024;[Epub]     CrossRef
• Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
  Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
  Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
  Korean Journal of Family Medicine.2021; 42(4): 269.     CrossRef
• Effects of an actual insulin injection demonstration on insulin acceptance among patients with T2DM: a pragmatic randomized controlled trial
  Atthayaporn Choomai, Apichai Wattanapisit, Orathai Tiangtam
  Romanian Journal of Internal Medicine.2021; 59(2): 151.     CrossRef
• Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
  Han Na Jang, Ye Seul Yang, Seong Ok Lee, Tae Jung Oh, Bo Kyung Koo, Hye Seung Jung
  Endocrinology and Metabolism.2019; 34(4): 382.     CrossRef
• Capacity and confidence building for general practitioners on optimum insulin use
  Sanjay Kalra, Prasun Deb, KalyanK Gangopadhyay, Sunil Gupta, Abhay Ahluwalia
  Journal of Family Medicine and Primary Care.2019; 8(10): 3096.     CrossRef
• Educational Strategies for Insulin Injection Therapy in Elderly Diabetic Patients
  Eun Chong Shin
  The Journal of Korean Diabetes.2018; 19(2): 101.     CrossRef
• Summary of Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017
  Byung-Wan Lee
  The Journal of Korean Diabetes.2018; 19(1): 31.     CrossRef
• New anti-diabetic agents
  Doo-Man Kim
  Journal of the Korean Medical Association.2017; 60(12): 992.     CrossRef

The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

Citations

Citations to this article as recorded by  

• Unveiling the potential of prodrug and drug-conjugate strategies in treatment of diabetes mellitus and its complications
  Neha V. Bhilare, Rushikesh Shedge, Prashant M. Tambe, Ajinkya More
  Medicinal Chemistry Research.2024; 33(3): 337.     CrossRef
• Simultaneous Estimation of Repaglinide and Voglibose in Newly Approved Fixed-Dose Combination by using UFLC: Application to ICH Q14 Concept and Comparative Method Greenness Assessment
  S.S. Panda, P.C. Rauta, V.S. Pulusu, S. Sahu, B.B. Dash
  Asian Journal of Chemistry.2023; 35(4): 887.     CrossRef
• Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach
  Ashok Kumar Das, Banshi Saboo, Rajeev Chawla, S. R. Aravind, Rajesh Rajput, Awadhesh K. Singh, J. J. Mukherjee, Ashok Jhingan, Parag Shah, Vaishali Deshmukh, Shailaja Kale, Shalini Jaggi, G. R. Sridhar, Rajnish Dhediya, Kumar Gaurav
  International Journal of Diabetes in Developing Countries.2023; 43(6): 856.     CrossRef
• The Gut Microbiome, Metformin, and Aging
  Sri Nitya Reddy Induri, Payalben Kansara, Scott C. Thomas, Fangxi Xu, Deepak Saxena, Xin Li
  Annual Review of Pharmacology and Toxicology.2022; 62(1): 85.     CrossRef
• Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial
  Wajiha Mahjabeen, Dilshad Ahmed Khan, Shakil Ahmed Mirza
  Complementary Therapies in Medicine.2022; 66: 102819.     CrossRef
• Letrozole: Pharmacology, toxicity and potential therapeutic effects
  Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Dhanushya Nagarajan, Vibhaa K K, Anagha V, Joshua Paul P, Tharani Priya T, Rituraj Chakraborty, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Abilash Valsala Gopalakrishnan
  Life Sciences.2022; 310: 121074.     CrossRef
• Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
  Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
  Korean Journal of Family Medicine.2021; 42(4): 269.     CrossRef
• Treatment intensification in type 2 diabetes management after the failure of two oral hypoglycemic agents: A non‐interventional comparative study
  Sirajudeen Shaik Alavudeen, Sultan M. Alshahrani, Easwaran Vigneshwaran, Noohu Abdulla Khan, Javid I. Mir, Abubakr T. M. Hussein
  International Journal of Clinical Practice.2021;[Epub]     CrossRef
• Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus
  Antonios Kousaxidis, Anthi Petrou, Vasiliki Lavrentaki, Maria Fesatidou, Ioannis Nicolaou, Athina Geronikaki
  European Journal of Medicinal Chemistry.2020; 207: 112742.     CrossRef
• Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2019;43;276-86)
  Hannah Seok, Tae Seo Sohn
  Diabetes & Metabolism Journal.2019; 43(4): 545.     CrossRef
• A Survey of the Structures of US FDA Approved Combination Drugs
  Pradipta Das, Michael D. Delost, Munaum H. Qureshi, David T. Smith, Jon T. Njardarson
  Journal of Medicinal Chemistry.2019; 62(9): 4265.     CrossRef
• Experimental design methodology for optimization and robustness determination in ion pair RP-HPLC method development: Application for the simultaneous determination of metformin hydrochloride, alogliptin benzoate and repaglinide in tablets
  Marianne A. Mahrouse, Nesrine T. Lamie
  Microchemical Journal.2019; 147: 691.     CrossRef
• The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea
  Da Young Lee, Ji Hee Yu, Sanghyun Park, Kyungdo Han, Nam Hoon Kim, Hye Jin Yoo, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim, Ji A. Seo
  Scientific Reports.2018;[Epub]     CrossRef
• Effect of Lifestyle Modification and Oral Anti-Diabetic Drugs on Metabolic Parameters in Recently Diagnosed Patientswith Uncomplicated Type 2 Diabetes Mellitus in Eastern India
  Nikhilesh Pradhan, Sidhartha Das, Anoj Kumar Baliarsinha, Ashirbad Parhi, Bijan Patnaik, Pramod Kumar Rout
  Journal of Diabetes Mellitus.2018; 08(02): 9.     CrossRef
• Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program
  Ja Young Jeon, Soo Jin Lee, Sieun Lee, Soo Jin Kim, Seung Jin Han, Hae Jin Kim, Dae Jung Kim, Young Seol Kim, Jeong Taek Woo, Kyu Jeung Ahn, Moonsuk Nam, Sei Hyun Baik, Yongsoo Park, Kwan‐Woo Lee
  Journal of Diabetes Investigation.2018; 9(5): 1144.     CrossRef

In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, the appropriate treatment should be selected considering the clinical characteristics of the patient, efficacy of the drug, side effects, and cost. In general, the use of metformin as the first treatment for oral hypoglycemic monotherapy is recommended because of its excellent blood glucose-lowering effect, relatively low side effects, long-term proven safety, low risk of hypoglycemia, and low weight gain. If metformin is difficult to use as a first-line treatment, other appropriate medications should be selected in view of the clinical situation. If the goal of achieving glycemic control is not achieved by monotherapy, a combination therapy with different mechanisms of action should be initiated promptly.

Citations

Citations to this article as recorded by  

• Diabetic Patients with COVID-19 Complications: Insights into Prevalence, Prognosis, Combination Medications, and Underlying Mechanisms
  Pranay Wal, Jyotsana Dwivedi, Ankita Wal, Shivangi Kushwaha
  Current Diabetes Reviews.2023;[Epub]     CrossRef
• Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
  Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
  Korean Journal of Family Medicine.2021; 42(4): 269.     CrossRef
• Synthesis, antidiabetic activity and molecular docking study of rhodanine-substitued spirooxindole pyrrolidine derivatives as novel α-amylase inhibitors
  Amani Toumi, Sarra Boudriga, Khaled Hamden, Mansour Sobeh, Mohammed Cheurfa, Moheddine Askri, Michael Knorr, Carsten Strohmann, Lukas Brieger
  Bioorganic Chemistry.2021; 106: 104507.     CrossRef
• Clinical Impact of Combination Therapy in Diabetic Neuropathy and Nephropathy
  Harmeet Kaur, Arvinder Kaur, Pankaj Kumar Prashar, Anamika Gautam, Ankita Sood, Sachin Kumar Singh, Monica Gulati, Narendra Kumar Pandey, Bimlesh Kumar
  Research Journal of Pharmacy and Technology.2021; : 3471.     CrossRef
• Type II diabetes mellitus: a review on recent drug based therapeutics
  Santwana Padhi, Amit Kumar Nayak, Anindita Behera
  Biomedicine & Pharmacotherapy.2020; 131: 110708.     CrossRef
• Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open‐label, active‐controlled, 12‐week study (STABLE II study)
  Soo Heon Kwak, You‐Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang‐Yong Kim, Jae Hyeon Kim
  Diabetes, Obesity and Metabolism.2020; 22(2): 173.     CrossRef
• Metabolomics approach to identify the active substances influencing the antidiabetic activity of Lagerstroemia species
  Mun-Ock Kim, Su Ui Lee, Heung Joo Yuk, Hyun-Jae Jang, Jae-Won Lee, Eun-Bin Kwon, Jin-Hyub Paik, SangHo Choi, Adek Nizar, Tran The Bach, Kongmany Sydara, Hang Jin, So-Yeun Woo, Sei-Ryang Oh, Hyung Won Ryu
  Journal of Functional Foods.2020; 64: 103684.     CrossRef
• Cardiometabolic diseases and active aging - polypharmacy in control
  Adriana Nancy Medeiros dos Santos, Dulcineia Rebecca Cappelletti Nogueira, Beatriz Aparecida Ozello Gutierrez, Rosa Yuka Sato Chubaci, Caroline Ribeiro de Borja Oliveira
  Revista Brasileira de Enfermagem.2020;[Epub]     CrossRef
• Anti-Diabetic Nephropathy Activities of Polysaccharides Obtained from Termitornyces albuminosus via Regulation of NF-κB Signaling in db/db Mice
  Chang Yang, Qi Feng, Huan Liao, Xinlei Yu, Yang Liu, Di Wang
  International Journal of Molecular Sciences.2019; 20(20): 5205.     CrossRef
• Specific PERK inhibitors enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes
  Min Joo Kim, Mi Na Kim, Se Hee Min, Dong-Sik Ham, Ji-Won Kim, Kun-Ho Yoon, Kyong Soo Park, Hye Seung Jung
  Metabolism.2019; 97: 87.     CrossRef
• A randomized, open‐label, multicentre, parallel‐controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti
  Lixin Guo, Li Chen, Baocheng Chang, Liyong Yang, Yu Liu, Bo Feng
  Diabetes, Obesity and Metabolism.2018; 20(12): 2740.     CrossRef
• Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association
  Sang Youl Rhee
  The Journal of Korean Diabetes.2018; 19(1): 15.     CrossRef

In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

Citations

Citations to this article as recorded by  

• Comparative Study on Efficacy of Empagliflozin Versus Sitagliptin, as an Add-on Therapy to Metformin in Type 2 Diabetic Patients
  Harsh Salankar, Sonali Rode, C. Arjun, Rajeeta Joseph, Gourav B. Deshmane, Radhika P. Vijayan
  Journal of Pharmacy and Bioallied Sciences.2024; 16(Suppl 1): S335.     CrossRef
• Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients
  Young-Hwan Park, Minji Sohn, So Yeon Lee, Soo Lim
  Diabetes & Metabolism Journal.2024; 48(2): 253.     CrossRef
• Association of preoperative blood glucose level with delirium after non-cardiac surgery in diabetic patients
  Soo Jung Park, Ah Ran Oh, Jong-Hwan Lee, Kwangmo Yang, Jungchan Park
  Korean Journal of Anesthesiology.2024; 77(2): 226.     CrossRef
• Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
  R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy
  Journal of Endocrinological Investigation.2023; 46(5): 855.     CrossRef
• Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study
  Hyeong Kyu Park, Kyoung‐Ah Kim, Kyung‐Wan Min, Tae‐Seo Sohn, In Kyung Jeong, Chul Woo Ahn, Nan‐Hee Kim, Ie Byung Park, Ho Chan Cho, Choon Hee Chung, Sung Hee Choi, Kang Seo Park, Seoung‐Oh Yang, Kwan Woo Lee
  Diabetes, Obesity and Metabolism.2023; 25(9): 2743.     CrossRef
• Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection
  Jong Chul Won
  The Journal of Korean Diabetes.2023; 24(2): 59.     CrossRef
• A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation
  Mazhar Ahmed, Asjad Saeed, Muhammad Zarar Khan, Sana Z Javaid, Farhan Aslam, Savida Ilyas Dar
  Cureus.2023;[Epub]     CrossRef
• Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extensio
  Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon
  Diabetes & Metabolism Journal.2023; 47(6): 808.     CrossRef
• Efficacy and Safety of Mulberry Twig Alkaloids Tablet for Treatment of Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Study
  Ling Qu, Xiao-chun Liang, Guo-qing Tian, Gai-li Zhang, Qun-li Wu, Xiu-mei Huang, Ya-zhong Cui, Yu-ling Liu, Zhu-fang Shen, Guo-qing Ma, Hao Lu, Yi Li, Hong Jiang, Xi-yan Yang, Guang-de Zhang, Chen-hua Yang
  Chinese Journal of Integrative Medicine.2022; 28(4): 304.     CrossRef
• Risk for Imbalanced Blood Glucose Pattern: Construct Analysis and Nursing Diagnosis Proposal
  Rafael Oliveira Pitta Lopes, Jéssica de Castro Santos, Hudson Carmo de Oliveira, Juliana Faria Campos, Cândida Caniçali Primo, Camila Takáo Lopes, Marcos Antônio Gomes Brandão
  Clinical Nursing Research.2022; 31(7): 1241.     CrossRef
• Long‐term clinical outcomes of oral antidiabetic drugs as fixed‐dose combinations: A nationwide retrospective cohort study
  Sang‐Jun Cho, In‐Sun Oh, Han Eol Jeong, Young Min Cho, Yul Hwangbo, Oriana Hoi Yun Yu, Ju‐Young Shin
  Diabetes, Obesity and Metabolism.2022; 24(10): 2051.     CrossRef
• Randomized Clinical Trial on Efficacy of Empagliflozin Versus Sitagliptin, In Addition to Metformin in Type 2 Diabetic Patients
  Muaz Mubashir, Mazhar Ahmed, Hassan Atique, Ahmed Wassan, Mehdi Naqvi, Muneeb Ullah
  Cureus.2022;[Epub]     CrossRef
• The Mediating Effect of Acceptance Action in the Relationship between Diabetes Distress and Self-stigma among Old Adults with Diabetes in South Korea
  Hyesun Kim, Kawoun Seo
  Journal of Korean Academy of Community Health Nursing.2022; 33(4): 446.     CrossRef
• Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes
  Juyoung Shin, Hyunah Kim, Hun-Sung Kim, Churlmin Kim, Whan-Seok Choi
  Korean Journal of Family Medicine.2021; 42(4): 269.     CrossRef
• Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
  Linong Ji, Jianhua Ma, Weiping Lu, Jingdong Liu, Jiao’e Zeng, Jialin Yang, Wei Li, Xiuzhen Zhang, Xinhua Xiao, Gen Takayanagi, Yi Wang
  Journal of Diabetes Investigation.2021; 12(4): 537.     CrossRef
• Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
  Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
  Diabetes & Metabolism Journal.2021; 45(2): 260.     CrossRef
• Blood glucose levels and bodyweight change after dapagliflozin administration
  Hyunah Kim, Seung‐Hwan Lee, Hyunyong Lee, Hyeon Woo Yim, Jae‐Hyoung Cho, Kun‐Ho Yoon, Hun‐Sung Kim
  Journal of Diabetes Investigation.2021; 12(9): 1594.     CrossRef
• Effects of liraglutide combined with metformin and Diamicron on glucose–lipid metabolism and islet β-cell function in elderly patients with type 2 diabetes mellitus
  Chunzhi Zhao, Xing Li, Jianhua Ma, Zhengtai Zhu, Hua Li, Fangli Lou, Yuefang Zhai, Hui Chen, Shujun Xiao, Qinhui Peng, Huilian Hua, Qing Zhang, Fangyong Lou
  All Life.2021; 14(1): 333.     CrossRef
• Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial
  Ling Qu, Xiaochun Liang, Guoqing Tian, Gaili Zhang, Qunli Wu, Xiumei Huang, Yazhong Cui, Yuling Liu, Zhufang Shen, Changqing Xiao, Yingfen Qin, Heng Miao, Yongyan Zhang, Ziling Li, Shandong Ye, Xuezhi Zhang, Jing Yang, Guiwen Cao, Yi Li, Gangyi Yang, Ji H
  Diabetes Care.2021; 44(6): 1324.     CrossRef
• Clinical Impact of Combination Therapy in Diabetic Neuropathy and Nephropathy
  Harmeet Kaur, Arvinder Kaur, Pankaj Kumar Prashar, Anamika Gautam, Ankita Sood, Sachin Kumar Singh, Monica Gulati, Narendra Kumar Pandey, Bimlesh Kumar
  Research Journal of Pharmacy and Technology.2021; : 3471.     CrossRef
• Effect of Voluntary Participation on Mobile Health Care in Diabetes Management: Randomized Controlled Open-Label Trial
  Da Young Lee, Seung-Hyun Yoo, Kyong Pil Min, Cheol-Young Park
  JMIR mHealth and uHealth.2020; 8(9): e19153.     CrossRef
• Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
  Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
  Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
• Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
  Jeong Mi Kim, Sang Soo Kim, Jong Ho Kim, Mi Kyung Kim, Tae Nyun Kim, Soon Hee Lee, Chang Won Lee, Ja Young Park, Eun Sook Kim, Kwang Jae Lee, Young Sik Choi, Duk Kyu Kim, In Joo Kim
  Diabetes & Metabolism Journal.2020; 44(1): 67.     CrossRef
• Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes
  Sang Ouk Chin, In Gyoon Ha, Sang Youl Rhee, Su Jin Jeong, Suk Chon, Sung Hoon Kim, Kyu Jeung Ahn, Sei Hyun Baik, Yongsoo Park, Moon Suk Nam, Kwan Woo Lee, Jeong Taek Woo
  International Journal of Endocrinology.2020; 2020: 1.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus
  Jae Hyun Bae, Hyung Jin Choi, Kang Ik Kevin Cho, Lee Kyung Kim, Jun Soo Kwon, Young Min Cho
  Diabetes & Metabolism Journal.2020; 44(2): 248.     CrossRef

• Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects

  
  Hyounggyoon Yoo, Yun Kim, In-Jin Jang, Kyung-Sang Yu, SeungHwan Lee
  Drug Design, Development and Therapy.2020; Volume 14: 5179.     CrossRef
• Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes
  Yun Kyung Cho, Jiwoo Lee, Yu Mi Kang, Jee Hee Yoo, Joong-Yeol Park, Chang Hee Jung, Woo Je Lee, Tatsuo Shimosawa
  PLOS ONE.2019; 14(8): e0220667.     CrossRef
• Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double‐blind, non‐inferiority trial
  Yonghyun Kim, Eun Seok Kang, Hak Chul Jang, Dong Jun Kim, Taekeun Oh, Eun Sook Kim, Nan‐Hee Kim, Kyung Mook Choi, Sung‐Rae Kim, JiYoung You, Se‐Jin Kim, Moon‐Kyu Lee
  Diabetes, Obesity and Metabolism.2019; 21(3): 631.     CrossRef
• Pharmacotherapy of Diabetes Focused on Stroke
  Young-Sang Lyu, Jin-Hwa Kim, Sang-Yong Kim
  Journal of the Korean Neurological Association.2019; 37(3): 235.     CrossRef
• Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2019;43;276-86)
  Hannah Seok, Tae Seo Sohn
  Diabetes & Metabolism Journal.2019; 43(4): 545.     CrossRef
• Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors
  Minyoung Lee, Jiyu Sun, Minkyung Han, Yongin Cho, Ji-Yeon Lee, Chung Mo Nam, Eun Seok Kang
  Diabetes Care.2019; 42(11): 2057.     CrossRef
• Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
  Tae Jung Oh, Jae Myung Yu, Kyung Wan Min, Hyun Shik Son, Moon Kyu Lee, Kun Ho Yoon, Young Duk Song, Joong Yeol Park, In Kyung Jeong, Bong Soo Cha, Yong Seong Kim, Sei Hyun Baik, In Joo Kim, Doo Man Kim, Sung Rae Kim, Kwan Woo Lee, Jeong Hyung Park, In Kyu
  Diabetes & Metabolism Journal.2019; 43(3): 276.     CrossRef
• 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
  Mee Kyoung Kim, Seung-Hyun Ko, Bo-Yeon Kim, Eun Seok Kang, Junghyun Noh, Soo-Kyung Kim, Seok-O Park, Kyu Yeon Hur, Suk Chon, Min Kyong Moon, Nan-Hee Kim, Sang Yong Kim, Sang Youl Rhee, Kang-Woo Lee, Jae Hyeon Kim, Eun-Jung Rhee, SungWan Chun, Sung Hoon Yu
  Diabetes & Metabolism Journal.2019; 43(4): 398.     CrossRef
• Medical Big Data Is Not Yet Available: Why We Need Realism Rather than Exaggeration
  Hun-Sung Kim, Dai-Jin Kim, Kun-Ho Yoon
  Endocrinology and Metabolism.2019; 34(4): 349.     CrossRef
• Monotherapy in Type 2 Diabetes Mellitus Patients 2017: A Position Statement of the Korean Diabetes Association
  Sang Youl Rhee
  The Journal of Korean Diabetes.2018; 19(1): 15.     CrossRef
• Glucose Control in Intensive Care Unit Patients: Recent Updates
  Sang Youl Rhee
  Journal of Neurocritical Care.2018; 11(2): 81.     CrossRef
• Educational Strategies for Insulin Injection Therapy in Elderly Diabetic Patients
  Eun Chong Shin
  The Journal of Korean Diabetes.2018; 19(2): 101.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
  Hyun Jin Kim
  The Journal of Korean Diabetes.2018; 19(1): 35.     CrossRef
• Fifty Years of Compassionate Care and Harmonious Collaboration of the Korean Diabetes Association: The 50th Anniversary of Korean Diabetes Association
  Jong Chul Won, Eun-Jung Rhee, Hyung Joon Yoo
  Diabetes & Metabolism Journal.2018; 42(6): 475.     CrossRef
• Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
  Kyung‐Ah Han, Suk Chon, Choon Hee Chung, Soo Lim, Kwan‐Woo Lee, SeiHyun Baik, Chang Hee Jung, Dong‐Sun Kim, Kyong Soo Park, Kun‐Ho Yoon, In‐Kyu Lee, Bong‐Soo Cha, Taishi Sakatani, Sumi Park, Moon‐Kyu Lee
  Diabetes, Obesity and Metabolism.2018; 20(10): 2408.     CrossRef
• Monotherapy in Patients with Type 2 Diabetes Mellitus
  Sang Youl Rhee, Hyun Jin Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Kyung Mook Choi, Jin Hwa Kim
  Diabetes & Metabolism Journal.2017; 41(5): 349.     CrossRef
• Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017
  Byung-Wan Lee, Jin Hwa Kim, Seung-Hyun Ko, Kyu Yeon Hur, Nan-Hee Kim, Sang Youl Rhee, Hyun Jin Kim, Min Kyong Moon, Seok-O Park, Kyung Mook Choi
  The Korean Journal of Internal Medicine.2017; 32(6): 967.     CrossRef
• New anti-diabetic agents
  Doo-Man Kim
  Journal of the Korean Medical Association.2017; 60(12): 992.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
  Hyun Jin Kim, Seok O Park, Seung-Hyun Ko, Sang Youl Rhee, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Byung-Wan Lee, Jin Hwa Kim, Kyung Mook Choi
  Diabetes & Metabolism Journal.2017; 41(6): 423.     CrossRef
• Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017
  Byung-Wan Lee, Jin Hwa Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Sang Youl Rhee, Hyun Jin Kim, Min Kyong Moon, Seok-O Park, Kyung Mook Choi
  Diabetes & Metabolism Journal.2017; 41(5): 367.     CrossRef